Versant Capital Management’s Cytokinetics CYTK Stock Holding History

Versant Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.51K	Buy	114 +28	+33%	+$2.13K	﹤0.01%	2349
2026 Q2	$7.33K	Sell	86 -42	-33%	-$3.02K	﹤0.01%	2334
2026 Q1	$8.44K	Buy	128 +86	+205%	+$5.47K	﹤0.01%	2210
2025 Q4	$2.67K	Buy	+42	New	+$2.61K	﹤0.01%	2400
2025 Q1	–	Sell	-11	Closed	-$517	–	2546
2024 Q4	$517	Buy	+11	New	+$571	﹤0.01%	2269
2021 Q2	–	Sell	-419	Closed	-$10K	–	1471
2021 Q1	$10K	Sell	419 -205	-33%	-$4.38K	﹤0.01%	783
2020 Q4	$12K	Sell	624 -39	-6%	-$713	﹤0.01%	671
2020 Q3	$14K	Hold	663	–	–	0.01%	535
2020 Q2	$15K	Buy	663 +314	+90%	+$5.89K	0.01%	498
2020 Q1	$4K	Buy	349 +12	+4%	+$153	﹤0.01%	823
2019 Q4	$3K	Hold	337	–	–	﹤0.01%	1055
2019 Q3	$3K	Hold	337	–	–	﹤0.01%	1078
2019 Q2	$3K	Buy	337 +256	+316%	+$2.47K	﹤0.01%	1084
2019 Q1	$0	Hold	81	–	–	﹤0.01%	1588
2018 Q4	$0	Hold	81	–	–	﹤0.01%	1499
2018 Q3	$0	Buy	+81	New	+$650	﹤0.01%	1538
2018 Q2	–	Sell	-21	Closed	–	–	1529
2018 Q1	$0	Buy	+21	New	+$180	﹤0.01%	1512

Other funds holding CYTK

MCP

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return

BCG

Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

EWP

Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return

Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return

GWM

Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

Versant Capital Management's CYTK Position: Q3 2026 in Review

Versant Capital Management increased its Cytokinetics (CYTK) stake by 33% in Q3 2026, buying an estimated $2.13K and bringing the position to 114 shares worth $7.51K. The position accounts for ﹤0.01% of the portfolio, ranked #2349.

Versant Capital Management first reported a position in CYTK in Q1 2018 and has held it in 17 quarters since. The position peaked at $15K in Q2 2020. 10 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

Versant Capital Management held 114 shares of Cytokinetics worth $7.51K as of Q3 2026.
Versant Capital Management bought 28 Cytokinetics shares in Q3 2026, an estimated $2.13K.
Cytokinetics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2349 holding.
Versant Capital Management first reported a position in Cytokinetics in Q1 2018 and has held it in 17 quarters since.
Versant Capital Management's Cytokinetics position peaked at $15K in Q2 2020.
10 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.